Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

A study on how  generic competition can rapidly lower the prices of drugs with high hepatitis C cure rates, like sofosbuvir and daclatasvir and help achieve global treatment scale-up, 12th January, 2016

Click here for more details.

/ News

Share the Post

Related Posts

IAC a community group in Indonesia demanding national food and drugs authority to expedite registration process of DAA medicines in Indonesia
Availability and Pricing of Generic Sofosbuvir in India – Updated 10 September 2015
Pricing and availability of generic Indian daclatasvir as on 7 March 2016
Read More
Story from Ajitshwor Wangkheirakpam, Manipur, India
Community group taking actions to enable greater access for generic HCV treatment
BMS’ patent bid for Hep C treatment Daclatasvir Challenged
Hepatitis C Treatment Snapshots: ledipasvir and sofosbuvir co-formulation
Asia-Pacific Aids Groups Express Deep Dismay At Conclusion Of Secretly Negotiated Trans-Pacific Partnership Agreement That Threatens Future Access To Affordable Generic Medicines And Sustainable Development Goals